Barts Cancer Institute, Centre for Haemato-Oncology, Queen Mary University of London, London, UK.
BHF/University Centre for Cardiovascular Science, Edinburgh Bioquarter, University of Edinburgh, Edinburgh, UK.
Br J Haematol. 2023 May;201(4):605-619. doi: 10.1111/bjh.18748. Epub 2023 Apr 17.
Whilst bone marrow adipocytes (BMAd) have long been appreciated by clinical haemato-pathologists, it is only relatively recently, in the face of emerging data, that the adipocytic niche has come under the watchful eye of biologists. There is now mounting evidence to suggest that BMAds are not just a simple structural entity of bone marrow microenvironments but a bona fide driver of physio- and pathophysiological processes relevant to multiple aspects of health and disease. Whilst the truly multifaceted nature of BMAds has only just begun to emerge, paradigms have shifted already for normal, malignant and non-malignant haemopoiesis incorporating a view of adipocyte regulation. Major efforts are ongoing, to delineate the routes by which BMAds participate in health and disease with a final aim of achieving clinical tractability. This review summarises the emerging role of BMAds across the spectrum of normal and pathological haematological conditions with a particular focus on its impact on cancer therapy.
虽然骨髓脂肪细胞 (BMAd) 长期以来一直受到临床血液病理学家的重视，但直到最近，随着新数据的出现，脂肪细胞龛才引起了生物学家的关注。越来越多的证据表明，BMAd 不仅是骨髓微环境的简单结构实体，而且是与健康和疾病多个方面相关的生理和病理生理过程的真正驱动因素。虽然 BMAd 的真正多面性才刚刚开始显现，但正常、恶性和非恶性造血的范式已经发生了转变，纳入了对脂肪细胞调节的看法。目前正在进行重大努力，以描绘 BMAd 参与健康和疾病的途径，最终目标是实现临床可操作性。本综述总结了 BMAd 在正常和病理血液学条件范围内的新兴作用，特别关注其对癌症治疗的影响。
